Drugmakers Novo Nordisk (NOV: N), Daiichi-Sankyo (TYO: 4568), Lundbeck (LUND: CO), AstraZeneca (LSE: AZN), UCB (Euronext: UCB) and Biogen (Nasdaq: BIIB) have been named and shamed by the UK pharma trade group.
The companies have been called out in advertisements for breaches of the Association of the British Pharmaceutical Industry (ABPI) code.
This means that the companies are accused of bringing discredit upon, and reducing confidence in, the pharmaceutical industry. In addition, UCB has been named for reducing confidence in the pharmaceutical industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze